NeoGenomics Inc (NEO) stock
Close on Nov 12, 2026Market cap $2.14BP/E –Yield –
NeoGenomics Inc grew revenue 11.1% to $787.75M over the twelve months to Sep 30, 2026. Free cash flow was -$28.58M. At the latest close the market valued the company at $2.14B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.14B
- P/E ratio
- –
- Price to sales
- 2.72
- Price to book
- 2.67
- Dividend yield
- –
- Free cash flow yield
- -1.34%
Fundamentals
- Revenue
- $787.75M
- Net income
- -$32.30M
- EPS, diluted
- -$0.25
- Free cash flow
- -$28.58M
- Book value per share
- $6.23
- Diluted shares
- 129M
Trading
- Next earnings
- Feb 16, 2027 (estimated, before the open)
- Previous close
- $16.83
- Open
- $16.45
- Day's range
- $16.11 – $16.69
- Volume
- 1,353,309
- Average volume (20 days)
- 1,765,477
- Index membership
- S&P SmallCap 600, Russell 2000, Russell 3000
- Beta (5 years)
- 1.73
- 52-week range
- $7.07 – $20.15
- RSI (14 days)
- 45.5
- Volatility (1 year)
- 53.6%
- Relative volume
- 0.61×
- WACC
- 12.2%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NEO | S&P 500 | Difference | NEO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.1% | -2.7% | +4.8 pts | ||
| 3 months | +0.7% | -1.7% | +2.5 pts | ||
| Year to date | +40.6% | +11.9% | +28.8 pts | ||
| 1 year | +65.4% | +12.0% | +53.4 pts | ||
| 3 years | +4.9% | +78.2% | −73.2 pts | +1.6% | +21.2% |
| 5 years | -60.5% | +73.2% | −133.8 pts | -17.0% | +11.6% |
| 10 years | +85.6% | +309.6% | −224.0 pts | +6.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NeoGenomics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- News
About NeoGenomics
Services-Testing Laboratories
NeoGenomics, Inc. provides oncology diagnostic testing, technical laboratory services, and professional test interpretations by specialized physicians and molecular experts. The company operates under a single reportable segment encompassing services such as molecular and next-generation sequencing testing, cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, morphologic analysis, and molecular residual disease testing. Additionally, it offers clinical trial and research support services, validation laboratory services, and oncology data solutions. Its customer base includes community-based oncology and pathology practices, hospital laboratories, reference laboratories, academic centers, and pharmaceutical companies.
Company profile, executives and historyNeoGenomics stock: common questions
What is NeoGenomics's stock price?
NEO closed at $16.54 on Nov 12, 2026, down 1.72% on the day. Over the past 52 weeks it traded between $7.07 and $20.15.
What is NeoGenomics's market cap?
NeoGenomics was worth $2.14B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NEO's P/E ratio?
NeoGenomics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.25), so it has no meaningful P/E ratio.
How much revenue does NeoGenomics make?
NeoGenomics reported revenue of $787.75M for the twelve months to Sep 30, 2026, up 11.1% from a year earlier.
Does NeoGenomics pay a dividend?
No. NeoGenomics has not paid a cash dividend over the last twelve months.
When does NeoGenomics report earnings next?
NeoGenomics is expected to report Q4 FY2026 results on Feb 16, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NEO stock performed over the past year?
Including dividends, NEO returned +65.4% over the past year, against +12.0% for the S&P 500.
How many NEO shares are sold short?
13M shares were sold short at the latest FINRA report, 10.31% of the float, or 6.7 days of average trading volume.
Who are NeoGenomics's competitors?
Companies most similar to NeoGenomics by business, industry and size include ULS, VCYT, MYGN, CSTL, BNR.
See a number that looks wrong?